NVP-LCQ195
NVP-LCQ195 (LCQ-195) is an inhibitor of CDK1/2/3/5/9. NVP-LCQ195 induces cell cycle arrest and eventual apoptotic cell death of multiple myeloma (MM) cells. NVP-LCQ195 triggers decreased amplitude of transcriptional signatures related to oncogenesis, drug resistance and stem cell renewal in MM cell lines[1].
Product Specifications
CAS Number
902156-99-4
Product Name Alternative
LCQ-195; AT9311
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NVP-LCQ195.html
Concentration
10mM
Purity
98.81
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
CS(=O)(N1CCC(NC(C2=C(NC(C3=C(Cl)C=CC=C3Cl)=O)C=NN2)=O)CC1)=O
Molecular Formula
C17H19Cl2N5O4S
Molecular Weight
460.33
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK3; CDK5; CDK6; CDK7; CDK9
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (156-3C11), CF594 conjugate, 0.1mg/mL
Human IgG Immunoglobulin (IG266), CF568 conjugate, 0.1mg/mL
MART-1 / Melan-A (M2-7C10), CF640R conjugate, 0.1mg/mL
Cytokeratin 8/18 (C-51), CF740 conjugate, 0.1mg/mL
